Skip to content

A study on a biochemical marker in a disease called Multiple Myeloma

Expression of Ki-67 in multiple myeloma - a clinicopathological study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/03/012755
Enrollment
50
Registered
2018-03-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- This prospective study will be conducted on total of 50 cases of bone marrow trephine biopsy specimens of Multiple Myeloma, diagnosed at our hospital.

Interventions

Intervention1: study group: 50 cases of Multiple Myeloma on the diagnostic trephine bone marrow biopsy specimens that are archived in the Department of Pathology, dharamshila hospital, delhi within ap

Sponsors

Dharamshila Hospital and Research Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 50 cases Multiple Myeloma diagnosed at our hospital will be examined and studied.

Exclusion criteria

Exclusion criteria: The following cases are excluded- 1) Post Chemotherapy (CT) patients 2) Post Radiotherapy (RT) patients 3) Plasmacytoma cases 4) Plasma cell leukemia cases

Design outcomes

Primary

MeasureTime frame
To estimate the proportion of the proliferating (Ki67 expressing) plasma cells in a series of patients with multiple myeloma.Timepoint: at the end of the every month within study duration

Secondary

MeasureTime frame
Clinico-pathologic correlation of Ki-67 index with various parameters viz. age, sex, performance status, hematological parameters (hemoglobin, total leukocyte count, platelet count and E.S.R.), biochemical parameters (total protein, albumin, A:G ratio etc.), number of osteolytic lesions, the Durie-Salmon staging, the International staging system, plasma cell percentage, plasma cell infiltration pattern in bone marrow and degree of fibrosis in bone marrowTimepoint: at the end of the every month within study duration

Countries

India

Contacts

Public ContactDr Kangana Sengar

Dharamshila Hospital and Research Centre

sanjaydeb@hotmail.com9717567779

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026